posted by James Swann
on January 12, 2022
Washington, D.C. – January 12, 2022 – Matt Eyles, President and CEO of AHIP, issued these comments after the Centers for Medicare & Medicaid Services (CMS) released a proposed National Coverage Determination decision for monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease, approved by the Food and Drug Administration (FDA):
“Americans deserve access to prescription drugs that are safe and effective, and we applaud CMS for putting patients first in their proposed coverage policy for monoclonal antibodies for treating patients with Alzheimer’s. We agree with CMS that there is a need to obtain more clinical data on efficacy, which will be essential to ensuring these new medications deliver real value to patients before broadening access. We look forward to commenting in greater detail during the comment period.”
Read AHIP’s letter to CMS, as CMS was conducting its National Coverage Determination analysis for these monoclonal antibodies.
AHIP is the national association whose members provide health care coverage, services, and solutions to hundreds of millions of Americans every day. We are committed to market-based solutions and public-private partnerships that make health care better and coverage more affordable and accessible for everyone. Visit www.ahip.org to learn how working together, we are Guiding Greater Health.